Translational Medical Oncology and Individualized Cancer Therapy - Andrés Muñoz
Clinical research
Gregorio Marañón Health Research Institute. Gregorio Marañón General University Hospital.
·Madrid ·
The Hospital General Universitario Gregorio Marañón, the hospital to which this group belongs, has
extensive experience within the multidisciplinary cancer unit in the treatment of this disease in its different stages.
different stages.
The generic objective of research in the Oncology Area is to generate reliable and scientifically relevant information on the
individualized cancer treatment, through translational research, which may allow for the selection of the most appropriate
antitumor treatment that provides more curative options and fewer sequelae for each patient. The selection
The therapy will be based essentially on the genetic/molecular profile of the patient and the tumor. The selection
The appropriate selection of cancer patients who are candidates for sophisticated antitumor therapies (target medical treatments),
high-definition radiotherapy, cell therapy, hemopoietic progenitor transplantation) available at our facilities.
center, will allow the most suitable choice to be made for each patient. In addition, the Area will study the cancer syndromes
and other high-risk cancer situations, in which a variety of interventions can be used to prevent cancer in the family and in other high-risk situations.
can be very effective in reducing the likelihood of disease occurrence.
The research group has a Clinical and Translational Research Unit integrated within the Department of
Medical Oncology, which is developing clinical trials in digestive tumors with new antitumor agents, and
technologies. It also has a Translational Oncology Laboratory (LAOT), which has been equipped to perform the following tests
genomic studies, also counting with the technology of the sequencing and genotyping unit and equipped with
for the development of cell biology techniques. It also features immunomagnetic separation technology.
on microfluidic support (IsofluxTM, FluxionBiosciences, Inc.), which in its performance indicates the increase of the
significant of the number of isolated CTCs, independent of EpCAM expression levels. With this
technology will be able to perform CTCs enumeration from liquid biopsy. This technology allows its application
in the counting and recovery of CTCs. In addition, the Hospital has an Animal Unit which provides
logistical support to researchers in order to carry out the entire xenotransplantation technology.
Strategic Axes
1. Strengthen alliances and collaborations in oncology.
2. Consolidation of research lines in oncology.
3. Training
4. Infrastructure consolidation
Examples of Lines of Research
Value of liquid biopsy as a predictor of response in oncology patients.
1. Development of preclinical models and PDXs
2. Organoid Development
3. Search for genomic profiles as predictors of response in the oncology patient
4. Immunotherapy for cancer disease.
5. Predictive models of thrombosis risk in patients with pancreatic cancer.
6. Predictive models of survival in pancreatic cancer (development of a prognostic score with 3 variables: hemoglobin, platelets and leukocytes).

Main publications in pancreatic cancer:

Andrés Muñoz

Principal Investigator

Group members

  • Andrés Muñoz
  • Pilar García Alfonso
  • Laura Ortega
  • José Manuel Asencio
  • José Ángel López Baena
  • Tatiana Massarrah
  • María del Monte

Other groups